Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ahead.

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...

Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...

Radiotherapy is a cornerstone of cancer care. However, in recent decades, Sweden has fallen behind in this area, both in ...

South Korea’s first domestically developed anti-cancer drug approved by the U.S. Food and Drug Administration (FDA), has ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Chase Malackowski was diagnosed with Ewing's Sarcoma at eight years old. After trialing a "single patient Investigational New ...